Brief: Actinium Highlights Oral Presentation At Eha 2024 Annual Congress
14/06/2024 13:50
June 14 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM HIGHLIGHTS ORAL PRESENTATION AT EHA 2024 ANNUAL
CONGRESS FEATURING IMPROVED OUTCOMES IN TP53 POSITIVE PATIENTS
RECEIVING IOMAB-B IN THE PHASE 3 SIERRA TRIAL
* LONG-TERM EFFICACY RESULTS IN PATIENTS WITH ACTIVE
RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA ALSO OBSERVED IN
SIERRA TRIAL
* LONG-TERM EFFICACY RESULTS SHOWS IOMAB-B WAS WELL
TOLERATED WITH
A FAVORABLE SAFETY PROFILE
* MEDIAN OVERALL SURVIVAL OF 5.49 MONTHS OBSERVED IN
PATIENTS WITH
A TP53 MUTATION RECEIVING IOMAB-B LED ALLOGENEIC BONE MARROW
TRANSPLANT
Source text for Eikon: ID:nPn8F1YkDa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities